CJ Bioscience Periodic Report
AI summary · Not investment advice
CJ Bioscience sold KRW 0.9 billion in Q3 and lost KRW 4.9 billion from its main business, a smaller loss than KRW 6.1 billion a year earlier.
Operating profit · 3 months
KRW -4.9 billion
Key facts
- Revenue (3 months)
- KRW 862.7 million
- Net income (3 months)
- KRW -4.8 billion
- Period
- Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
- Revenue (prior-year 3 months)
- KRW 737.9 million
- Revenue (year to date)
- KRW 2.5 billion
- Operating profit (prior-year 3 months)
- KRW -6.1 billion
- Operating profit (year to date)
- KRW -16.7 billion
- Net income (prior-year 3 months)
- KRW -5.8 billion
- Net income (year to date)
- KRW -16.1 billion
Commentary
AI commentary · Not investment advice
What happened
CJ Bioscience filed its quarterly report on a consolidated basis for the third quarter of 2026. Sales for the latest 3 months were KRW 862.7 million. That is 16.9% higher than the same 3 months a year earlier, and 4.0% lower than the previous quarter. Cumulative sales this year are KRW 2.54 billion.
In the company's terms
Operating profit (money earned from the core business) for the latest 3 months was a loss of KRW 4.93 billion. A year earlier, the same period showed a loss of KRW 6.08 billion. The cumulative operating loss this year is KRW 16.67 billion.
What changes for shareholders
Net income (the final profit after taxes and all other items) for the latest 3 months was a loss of KRW 4.77 billion. A year earlier, it was a loss of KRW 5.83 billion. The cumulative net loss this year is KRW 16.10 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
C